Farnesol disrupts hypoxia-driven EMT signaling in lung cancer spheroids
Farnesol disrupts hypoxia‑driven EMT signaling in lung cancer spheroids.
Farnesol is a naturally occurring sesquiterpene alcohol that inhibits HIF1A, COX2, PCAF, VEGF and MMP2/9 signaling, reverses the E‑cadherin loss associated with epithelial‑to‑mesenchymal transition (EMT) and reduces migration and invasion of A549 lung adenocarcinoma cells in 2D and 3D spheroid culture systems.
The compound reverses key transcriptional and proteomic drivers of EMT and hypoxia‑induced metastasis in non‑small cell lung cancer (NSCLC) cells, suggesting a potential antimetastatic therapeutic strategy.
Bizonyítékszint: Számítógépes vagy elméleti. Modellből vagy adatbányászatból származó jel.
Kapcsolódó jelek
- Telisotuzumab Vedotin + Osimertinib for Non‑Small Cell Lung Cancer
- Ramucirumab plus erlotinib in patients with untreated, EGFR‑mutated, advanced non‑small‑cell lung cancer (RELAY): a randomised, double‑blind, placebo‑controlled, phase 3 trial
- Recent advancements in lung cancer research: a narrative review
- Advances in Non-Small Cell Lung Cancer: Current Insights and Future Directions
- Structured proxy features for multimodal NSCLC survival prediction from pretreatment CT